456 related articles for article (PubMed ID: 18662281)
1. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma.
Kim JH; Park JW; Koh DW; Lee WJ; Kim CM
Liver Int; 2009 Feb; 29(2):203-7. PubMed ID: 18662281
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of lamivudine therapy for decompensated liver cirrhosis due to hepatitis B virus with or without hepatocellular carcinoma.
Hiraoka A; Michitaka K; Kumagi T; Kurose K; Uehara T; Hirooka M; Yamashita Y; Kubo Y; Miyaoka H; Iuchi H; Okada S; Ohmoto M; Yamamoto K; Horiike N; Onji M
Oncol Rep; 2005 Jun; 13(6):1159-63. PubMed ID: 15870937
[TBL] [Abstract][Full Text] [Related]
3. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
[TBL] [Abstract][Full Text] [Related]
4. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
Kuzuya T; Katano Y; Kumada T; Toyoda H; Nakano I; Hirooka Y; Itoh A; Ishigami M; Hayashi K; Honda T; Goto H
J Gastroenterol Hepatol; 2007 Nov; 22(11):1929-35. PubMed ID: 17914972
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma.
Kim JH; Park JW; Kim TH; Koh DW; Lee WJ; Kim CM
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):813-9. PubMed ID: 17524569
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy.
Nagamatsu H; Itano S; Nagaoka S; Akiyoshi J; Matsugaki S; Kurogi J; Tajiri N; Yamasaki S; Koga H; Torimura T; Kumashiro R; Sata M
Am J Gastroenterol; 2004 Dec; 99(12):2369-75. PubMed ID: 15571585
[TBL] [Abstract][Full Text] [Related]
8. [The relationship between HBV genotypes and the efficacy of antiviral therapies in hepatitis B e antigen- positive patients].
Zou HB; Zhu LM; Zhao GM; Liang SR; Li J; Lu CZ; Li H
Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):425-7. PubMed ID: 17594806
[TBL] [Abstract][Full Text] [Related]
9. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation.
Woo HY; Choi JY; Jang JW; You CR; Bae SH; Yoon SK; Yang JM; Choi SW; Han NI; Kim DG
J Med Virol; 2008 Nov; 80(11):1891-9. PubMed ID: 18814257
[TBL] [Abstract][Full Text] [Related]
10. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.
Di Marco V; Marzano A; Lampertico P; Andreone P; Santantonio T; Almasio PL; Rizzetto M; Craxì A;
Hepatology; 2004 Oct; 40(4):883-91. PubMed ID: 15382125
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
13. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection.
Li N; Lai EC; Shi J; Guo WX; Xue J; Huang B; Lau WY; Wu MC; Cheng SQ
Ann Surg Oncol; 2010 Jan; 17(1):179-85. PubMed ID: 19727956
[TBL] [Abstract][Full Text] [Related]
15. The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis.
Kilic ZM; Kuran S; Akdogan M; Cicek B; Oguz D; Odemis B; Sasmaz N
Adv Ther; 2008 Mar; 25(3):190-200. PubMed ID: 18385953
[TBL] [Abstract][Full Text] [Related]
16. Lamivudine treatment in patients with hepatitis B virus induced liver cirrhosis.
Cetin K; Sabahattin K; Kadir D; Ahmet D; Ziyaettin D; Selim B; Mürüvvet B; Fatih B; Güngör B; Zeynel M; Yilmaz C; Atilla O
Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccxcv-ccxcvii. PubMed ID: 15244206
[TBL] [Abstract][Full Text] [Related]
17. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
18. Chronic cirrhotic hepatitis B patients with a high incidence of hepatic decompensation after viral breakthrough with lamivudine-resistant mutants and during rescue treatment.
Joo MK; Yeon JE; Kim JH; Jung YK; Lee SJ; Kim JH; Yim HJ; Byun KS; Park JJ; Kim JS; Bak YT
Scand J Gastroenterol; 2008; 43(12):1514-21. PubMed ID: 18663665
[TBL] [Abstract][Full Text] [Related]
19. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety.
Jonas MM; Little NR; Gardner SD;
J Viral Hepat; 2008 Jan; 15(1):20-7. PubMed ID: 18088241
[TBL] [Abstract][Full Text] [Related]
20. Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance.
Hui JM; George J; Liddle C; Lin R; Samarasinghe D; Crewe E; Farrell GC
Am J Gastroenterol; 2002 Apr; 97(4):1003-9. PubMed ID: 12003380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
